RT Journal Article SR Electronic T1 Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines JF RMD Open JO RMD Open FD EULAR SP e000784 DO 10.1136/rmdopen-2018-000784 VO 4 IS Suppl 1 A1 Alain Meyer A1 Carlo Alberto Scirè A1 Rosaria Talarico A1 Tobias Alexander A1 Zahir Amoura A1 Tadej Avcin A1 Simone Barsotti A1 Lorenzo Beretta A1 Jelena Blagojevic A1 Gerd Burmester A1 Ilaria Cavazzana A1 Patrick Cherrin A1 Laura Damian A1 Andrea Doria A1 João Eurico Fonseca A1 Federica Furini A1 Ilaria Galetti A1 Frederic Houssiau A1 Thomas Krieg A1 Maddalena Larosa A1 David Launay A1 Raquel Campanilho-Marques A1 Thierry Martin A1 Marco Matucci-Cerinic A1 Pia Moinzadeh A1 Carlomaurizio Montecucco A1 Maria Francisca Moraes-Fontes A1 Luc Mouthon A1 Rossella Neri A1 Sabrina Paolino A1 Yves Piette A1 Simona Rednic A1 Farah Tamirou A1 Angela Tincani A1 Natasa Toplak A1 Stefano Bombardieri A1 Eric Hachulla A1 Ulf Mueller-Ladner A1 Matthias Schneider A1 Vanessa Smith A1 Ana Vieira A1 Maurizio Cutolo A1 Marta Mosca A1 Lorenzo Cavagna YR 2019 UL http://rmdopen.bmj.com/content/4/Suppl_1/e000784.abstract AB Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and inflammation, but in antisynthetase syndrome arthritis and interstitial lung disease are more frequent and often inaugurate the disease. Clinical practice guidelines (CPGs) have been proposed for IIMs, but they are sparse and heterogeneous. This work aimed at identifying: i) current available CPGs for IIMs, ii) patients ’ and clinicians’ unmet needs not covered by CPGs. It has been performed in the framework of the European Reference Network on rare and complex connective tissue and musculoskeletal diseases (ReCONNET), a network of centre of expertise and patients funded by the European Union’s Health Programme. Fourteen original CPGs were identified, notably recommending that: i) extra-muscular involvements should be assessed; ii) corticosteroids and methotrexate or azathioprine are first-line therapies of IIMs. ii) IVIG is a treatment of resistant-DM that may be also used in other resistant-IIMs; iii) physical therapy and sun protection (in DM patients) are part of the treatment; v) tumour screening for patients with DM include imaging of chest, abdomen, pelvis and breast (in woman) along with colonoscopy (in patients over 50 years); vi) disease activity and damages should be monitor using standardised and validated tools. Yet, only half of these CPGs were evidence-based. Crucial unmet needs were identified both by patients and clinicians. In particular, there was a lack of large multidisciplinary working group and of patients ’ preferences. The following fields were not or inappropriately targeted: diagnosis; management of extra-muscular involvements other than skin; co-morbidities and severe manifestations.